Special Issue

Advances in Vector-Based Immunization: Exploring the Next Horizon of Vaccine Technology

Message from the Guest Editor

Vector-based immunization offers numerous advantages, including the potential to stimulate broader and more robust immune responses, co-deliver multiple antigens from various pathogens, and rapidly adapt to new and evolving infectious agents. This platform is especially crucial when we consider pathogens with high mutation rates or those for which traditional vaccine approaches have been less successful. In view of your deep expertise and commitment to this field, we invite you to contribute an original article, observation, report, or review in order to underscore the following aspects of this field:

- The development of vector vaccines against infectious diseases such as coronavirus, influenza virus, HIV, etc.
- Universal vaccines against pathogens with high mutation rates, such as SARS-CoV-2 and influenza viruses.
- The underlying mechanisms and biology of vector-based immunization.
- Recent successes and failures in the realm of vector-based vaccine candidates.
- Challenges and strategies in circumventing host–vector interactions that may diminish vaccine efficacy.
- The future trajectory of vector-based immunization in addressing global infectious threats.

Guest Editor

Dr. Jingen Zhu

Department of Biology, Catholic University of America, Washington, DC, USA

Deadline for manuscript submissions

closed (31 May 2025)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/183564

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI